文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

镰状细胞特质合并肾脏共病与急性肾衰竭同COVID-19不良结局的关联

Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait.
PubMed 文献 · JAMA Intern Med · 2022-01-01
一句话结论在百万退伍军人计划中,非洲裔镰状细胞特质者COVID-19死亡风险增高(OR 1.77),急性肾衰竭部分介导该效应。

本研究基于百万退伍军人计划(MVP)的遗传关联数据,纳入2729例镰状细胞特质(SCT)者(其中353例患COVID-19)和129848例SCT阴性者(其中13488例患COVID-19),数据收集于2020年3月至2021年2月。SCT与既存肾脏共病(慢性肾病、糖尿病肾病、高血压肾病)、肺栓塞和脑血管病相关。在非洲裔个体中,SCT与COVID-19死亡率增高相关(n=3749;OR 1.77;95%CI 1.13-2.77;P=0.01),且COVID-19后60天内急性肾衰竭发生率增高。反事实中介分析估计,SCT对COVID-19死亡总效应的20.7%(95%CI -3.8%至56.0%)由急性肾衰竭介导。

要点

  • 在非洲裔MVP参与者中,镰状细胞特质与COVID-19死亡率增高相关(n=3749;OR 1.77;95%CI 1.13-2.77;P=0.01)。
  • 镰状细胞特质与既存慢性肾病、糖尿病肾病、高血压肾病、肺栓塞和脑血管病病史相关。
  • COVID-19后60天内,镰状细胞特质与急性肾衰竭发生率增高相关。
  • 中介分析估计SCT对COVID-19死亡总效应的20.7%(95%CI -3.8%至56.0%)由急性肾衰竭介导,置信区间跨0。
  • SCT在非洲裔人群中占7.8%,与COVID-19的关联按祖先背景分析并调整了性别、年龄、年龄平方和祖先主成分。

适用人群与场景

  • 百万退伍军人计划(MVP)参与者,具备COVID-19临床数据,数据收集于2020年3月至2021年2月。
  • 分析按祖先背景分层(非洲裔等),调整性别、年龄、年龄平方和祖先主成分。
  • SCT定义为携带1个血红蛋白β镰状等位基因(rs334-T)和1个正常β等位基因。

研究设计与关键结果

  • 遗传关联研究:COVID-19临床数据包括2729例SCT者(353例患COVID-19)和129848例SCT阴性者(13488例患COVID-19);132577名MVP参与者索引日期平均(SD)年龄64.8(13.1)岁。
  • SCT在非洲裔个体中占7.8%,与慢性肾病、糖尿病肾病、高血压肾病、肺栓塞和脑血管病病史相关。
  • 在4项COVID-19临床结局中,SCT与非洲裔个体COVID-19死亡率增高相关(n=3749;OR 1.77;95%CI 1.13-2.77;P=0.01)。
  • COVID-19后60天内,SCT与急性肾衰竭发生率增高相关。
  • 反事实中介框架估计,SCT对COVID-19死亡总效应的20.7%(95%CI -3.8%至56.0%)由急性肾衰竭介导。

证据类型、等级与局限

  • 证据类型:遗传关联研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于非洲裔镰状细胞特质者,应关注其既存肾脏共病(慢性肾病、糖尿病肾病、高血压肾病)及肺栓塞、脑血管病病史。
  • 镰状细胞特质者感染COVID-19后,需监测急性肾衰竭的发生。
  • 作者结论:镰状细胞特质与既存肾脏共病、COVID-19死亡率增高和肾脏疾病负担相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sickle cell trait (SCT), defined as the presence of 1 hemoglobin beta sickle allele (rs334-T) and 1 normal beta allele, is prevalent in millions of people in the US, particularly in individuals of African and Hispanic ancestry. However, the association of SCT with COVID-19 is unclear.

OBJECTIVE: To assess the association of SCT with the prepandemic health conditions in participants of the Million Veteran Program (MVP) and to assess the severity and sequelae of COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: COVID-19 clinical data include 2729 persons with SCT, of whom 353 had COVID-19, and 129 848 SCT-negative individuals, of whom 13 488 had COVID-19. Associations between SCT and COVID-19 outcomes were examined using firth regression. Analyses were performed by ancestry and adjusted for sex, age, age squared, and ancestral principal components to account for population stratification. Data for the study were collected between March 2020 and February 2021.

EXPOSURES: The hemoglobin beta S (HbS) allele (rs334-T).

MAIN OUTCOMES AND MEASURES: This study evaluated 4 COVID-19 outcomes derived from the World Health Organization severity scale and phenotypes derived from International Classification of Diseases codes in the electronic health records.

RESULTS: Of the 132 577 MVP participants with COVID-19 data, mean (SD) age at the index date was 64.8 (13.1) years. Sickle cell trait was present in 7.8% of individuals of African ancestry and associated with a history of chronic kidney disease, diabetic kidney disease, hypertensive kidney disease, pulmonary embolism, and cerebrovascular disease. Among the 4 clinical outcomes of COVID-19, SCT was associated with an increased COVID-19 mortality in individuals of African ancestry (n = 3749; odds ratio, 1.77; 95% CI, 1.13 to 2.77; P = .01). In the 60 days following COVID-19, SCT was associated with an increased incidence of acute kidney failure. A counterfactual mediation framework estimated that on average, 20.7% (95% CI, -3.8% to 56.0%) of the total effect of SCT on COVID-19 fatalities was due to acute kidney failure.

CONCLUSIONS AND RELEVANCE: In this genetic association study, SCT was associated with preexisting kidney comorbidities, increased COVID-19 mortality, and kidney morbidity.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Verma A, Huffman JE, Gao L, et al. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Intern Med. 2022. PMID: 35759254. doi:10.1001/jamainternmed.2022.2141

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。